Missouri Pharmacy Program – Preferred Drug List

Thrombocytopenia Treatment Agents

Effective 08/29/2019
Revised 10/03/2019

Preferred Agents for Chronic Immune Thrombocytopenia

• NPlate®
• Promacta®

Non-Preferred Agents for Chronic Immune Thrombocytopenia

• Doptelet®
• Tavalisse™

Preferred Agents for short-term use in patients with chronic liver disease who are scheduled to undergo a procedure

• Doptelet®
• Mulpleta®

Non-Preferred Agents for short-term use in patients with chronic liver disease who are scheduled to undergo a procedure

Approval Criteria

• For Chronic Immune Thrombocytopenia
  o Doptelet, NPlate, Promacta, or Tavalisse
  o Appropriate age:
    • 18 and older for Tavalisse or Doptelet
  o Documented trial of a corticosteroid (defined as 30 out of 60 days)
  o Failure to achieve desired therapeutic outcomes with trial on 2 preferred agents
  o Documented ADE/ADR to preferred agents

• For patients with chronic liver disease who are scheduled to undergo a procedure: Doptelet or Mulpleta only

Denial Criteria

• Lack of adequate trial on required preferred agents
• Therapy will be denied if no approval criteria are met
• Drug Prior Authorization Hotline: (800) 392-8030